Veradermics
MANE
119.52
-4.87
-3.92%
Veradermics
US · MANE
#2148 by market cap
Listed 2026
119.52
-4.87
-3.92%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:02
Recent news
-
Rating change
Analysts Are Bullish on Top NA Stocks: Veradermics, Incorporated (MANE), Bicara Therapeutics Inc. (BCAX)TipRanks · 2026/8/12
-
Rating change
Jefferies Maintains Veradermics(MANE.US) With Buy Rating, Maintains Target Price $182Market Newswire · 2026/7/16
-
Rating change
Needham Maintains Veradermics(MANE.US) With Buy Rating, Maintains Target Price $164Market Newswire · 2026/8/13
-
Rating change
B. Riley Analyst Initiates Coverage of Veradermics Stock (MANE) With a Buy RatingTipRanks · 2026/7/16
-
Rating change
Citi Maintains Veradermics(MANE.US) With Buy Rating, Maintains Target Price $160Market Newswire · 2026/10/20
-
Citi Maintains Veradermics(MANE.US) With Buy Rating, Maintains Target Price $175Market Newswire · 2026/11/10
-
Veradermics(MANE.US) 10% Shareholder Sells US$75.19 Million in Common StockMarket Newswire · 2026/11/14
-
Leerink Partners Maintains Veradermics(MANE.US) With Buy Rating, Raises Target Price to $185Market Newswire · 2026/11/13
-
Rating change
Jefferies Maintains Veradermics(MANE.US) With Buy Rating, Maintains Target Price $138Market Newswire · 2026/6/16
-
Rating change
Jefferies Maintains Veradermics(MANE.US) With Buy Rating, Raises Target Price to $182Market Newswire · 2026/7/7
-
Rating change
Analysts Conflicted on These NA Names: HeartFlow, Inc. (HTFL), Phoenix Education Partners, Inc. (PXED) and Veradermics, Incorporated (MANE)TipRanks · 2026/7/15
-
Citi Maintains Veradermics(MANE.US) With Buy Rating, Raises Target Price to $175Market Newswire · 2026/11/10
-
Rating change
LifeSci Capital Maintains Veradermics(MANE.US) With Buy Rating, Maintains Target Price $170Market Newswire · 2026/8/12
-
Rating change
Leerink Partners Maintains Veradermics(MANE.US) With Buy Rating, Raises Target Price to $150Market Newswire · 2026/11/10
-
Form 144 | Veradermics(MANE.US) 10% Stockholder Proposes to Sell 37.6 Million in Common StocksMarket Newswire · 2026/11/12
-
Rating change
LifeSci Capital Maintains Veradermics(MANE.US) With Buy Rating, Raises Target Price to $170Market Newswire · 2026/7/15
-
Rating change
Needham Maintains Veradermics(MANE.US) With Buy Rating, Raises Target Price to $164Market Newswire · 2026/7/15
-
Rating change
Citi Maintains Veradermics(MANE.US) With Buy Rating, Raises Target Price to $160Market Newswire · 2026/7/16
-
Rating change
Citi Maintains Veradermics(MANE.US) With Buy Rating, Maintains Target Price $135Market Newswire · 2026/6/22
-
Rating change
B. Riley Securities Initiates Veradermics(MANE.US) With Buy Rating, Announces Target Price $170Market Newswire · 2026/7/15
-
Rating change
Jefferies Maintains Veradermics(MANE.US) With Buy Rating, Raises Target Price to $138Market Newswire · 2026/5/14
-
Rating change
LifeSci Capital Initiates Veradermics(MANE.US) With Buy Rating, Announces Target Price $135Market Newswire · 2026/6/16
-
Rating change
Citi Maintains Veradermics(MANE.US) With Buy Rating, Raises Target Price to $135Market Newswire · 2026/5/18
-
Veradermics(MANE.US) Officer Sells US$7.28 Million in Common StockMarket Newswire · 2026/8/19
-
Rating change
Needham Initiates Veradermics(MANE.US) With Buy Rating, Announces Target Price $136Market Newswire · 2026/6/2
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 20:02:23 · For reference only, not investment advice and not tailored to your situation.
Veradermics discussion 0 comments